Pfizer has launched a late-stage clinical trial to test a vaccine that could protect against Lyme disease, the company announced Monday.
could be the first human vaccine for the tick-borne illness in the U.S. in 2 decades. One other vaccine – LYMErix – was used in the past but was discontinued in 2002.
In the phase III trial by Pfizer and Valneva, a French biotech company, the vaccine candidate VLA15 will be tested for efficacy, safety, and immune response. The trial will enroll about 6,000 healthy adults and children, ages 5 and older. Data from phase II studies showed a strong immune response in adults and children, with “acceptable safety and tolerability profiles,” Pfizer said.
“We are extremely pleased to reach this important milestone in the development of VLA15,” Juan Carlos Jaramillo, MD, chief medical officer of Valneva, said in the statement.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pfizer Begins Trial for Lyme Disease VaccineIf the trial succeeds, the vaccine could be the first human vaccine for the tick-borne illness in the US in two decades.
続きを読む »
Pfizer just started a late-stage clinical trial of a Lyme disease vaccineIf the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
続きを読む »
FDA Approves Pfizer-BioNTech Booster Dose for Children Ages 5 to 11 as Cases RiseInfectious disease experts explain what parents need to know.
続きを読む »
FDA authorizes Pfizer-BioNTech booster shots for kids 5-11The FDA has authorized booster doses of the Pfizer-BioNTech COVID-19 vaccine for kids 5-11.
続きを読む »
Pfizer-BioNTech seeks FDA authorization for a COVID booster shot for kids 5-11Pfizer and BioNTech have requested that the Food and Drug Administration authorize a COVID-19 booster shot for children ages 5-11.
続きを読む »
Pfizer-BioNTech will seek authorization for second COVID booster for older adultsPfizer is planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people 65 and older.
続きを読む »